Contributions
Abstract: EP1343
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: The incidence of multiple sclerosis (MS) is increasing around the world. However, it is controverted if it is a real change or just a consequence of the improvement in diagnostic procedures and the update of the criteria.
Objectives: To determinate the actual incidence of MS and analyze its temporal trend in our reference population.
Methods: A capture-recapture study was conducted in Santiago de Compostela (north-west of Spain) between 2010 and 2015, in order to determinate the current incidence of MS. Mc Donald 2010 criteria were used to identify cases. Moreover, clinical charts were reviewed to determinate if Poser criteria were also fulfilled. The results were compared with those obtained for another study done with the same methodology in the same area between 1998-2002.
Results: The mean incidence was 8.02 cases/100.000 habitants/year. It was almost double in women (10.08 vs 5.63 cases/100.000 habitants/year). Mean age at the first symptom was 34 years (SD:10.4), 67.39% were female and 89.13% were relapsing remitting MS. Previous incidence was lower (5.3 cases/100.000 habitants/year), nevertheless the difference was not significant (p=0.134).
Conclusions: An increment in the incidence of MS was detected in our area. It is the highest rate of Spain as it was in the previous study.
Disclosure: Costa Arpín E.: has served as speaker or consultant for Biogen Idec , Merck Serono, Bayer Health Care, Genzyme, TEVA and UCB Pharma. Puente Hernández M and Lagorio A: nothing to disclosure. Arias Gómez M has served aadvisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.
Abstract: EP1343
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Epidemiology
Introduction: The incidence of multiple sclerosis (MS) is increasing around the world. However, it is controverted if it is a real change or just a consequence of the improvement in diagnostic procedures and the update of the criteria.
Objectives: To determinate the actual incidence of MS and analyze its temporal trend in our reference population.
Methods: A capture-recapture study was conducted in Santiago de Compostela (north-west of Spain) between 2010 and 2015, in order to determinate the current incidence of MS. Mc Donald 2010 criteria were used to identify cases. Moreover, clinical charts were reviewed to determinate if Poser criteria were also fulfilled. The results were compared with those obtained for another study done with the same methodology in the same area between 1998-2002.
Results: The mean incidence was 8.02 cases/100.000 habitants/year. It was almost double in women (10.08 vs 5.63 cases/100.000 habitants/year). Mean age at the first symptom was 34 years (SD:10.4), 67.39% were female and 89.13% were relapsing remitting MS. Previous incidence was lower (5.3 cases/100.000 habitants/year), nevertheless the difference was not significant (p=0.134).
Conclusions: An increment in the incidence of MS was detected in our area. It is the highest rate of Spain as it was in the previous study.
Disclosure: Costa Arpín E.: has served as speaker or consultant for Biogen Idec , Merck Serono, Bayer Health Care, Genzyme, TEVA and UCB Pharma. Puente Hernández M and Lagorio A: nothing to disclosure. Arias Gómez M has served aadvisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. Prieto González JM. has served as advisor, consultant and speaker for Bayer HealthCare Pharmaceuticals, Biogen Idec Inc., Genzyme Corporation, Novartis Pharmaceuticals Corporation, Sanofi Aventis and Teva Pharmaceuticals. He also has received grants for clinical research from Biogen Idec Inc and Novartis Pharmaceuticals Corporation.